# OnCo record nct05956587 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05956587/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05956587", "NCT05956587" ;
  schema:name "A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other"@en ;
  schema:description "A phase 2 trial of Izalontamab brengitecan in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05956587/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05956587> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-01-29" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/nasopharyngeal/>, <https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/bispecific-adc/> ;
  onco:drugs <https://onco.cc/drugs/izalontamab-brengitecan/> ;
  onco:companies <https://onco.cc/companies/systimmune/> .